Welcome to AGILE R100

Reliable biophysical characterization, at your fingertips.

THE POWER TO ACHIEVE

The easy-to-learn AGILE R100 assay makes it simple to get dose-response curves and kinetic binding data earlier in the drug discovery process when you need it most. Built with highly sensitive, proprietary Field Effect Biosensing (FEB) technology, AGILE R100 enables detection even in crude samples using minimal volume, giving you control over the complete characterization of your biomolecules. 

Optimize leads with a novel label-free method and achieve measurements never before possible!

High sensitivity with AGILE R100

SENSITIVE

10 µL of sample

11-log dynamic range

Label-free measurements with AGILE R100

SIMPLE

Label-free reduces

design complexity

AGILE R100 is a benchtop tool

PORTABLE

Personal system

weighing 2 lbs.

AGILE R100 provides fast measurements in 2 minutes

FAST

Assay development

Sense in 2 minutes

SENSITIVE LABEL-FREE RESULTS WITH AGILE R100

AGILE R100’s open-pipetting design enables on-the-fly assay modification, vastly reducing assay development time.
See how it’s used in this 1:32 video!

EVENTS

Join us to learn more about the AGILE R100 orthogonal approach to biophysical characterization!

Nanomedical Diagnostics 2018 Society for Laboratory Automation and Screening Conference booth

2018 Society for Laboratory Automation and Screening

We’ll be in Booth 332 at the 2018 the Society for Laboratory Automation and Screening (SLAS) conference in San Diego from Feb. 3-7 to launch AGILE R200, the only high-throughput biophysical data platform compatible with automated liquid handlers.

PARTNERS

CRADA with the CDC to evaluate direct electronic detection for disease diagnostic systems.
DARPA grant awarded to develop hand-held drug therapeutic monitoring devices.
Mayo Clinic evaluating the diagnostic capabilities of field effect biosensor chips.
Stanford School of Medicine using AGILE R100 for in vitro kinetic binding data.